(Difference between revisions)
Line 29: Line 29:
For more details, please see our [[Team:Caltech/Project|project]] page.
For more details, please see our [[Team:Caltech/Project|<font style="color:#BB4400">project</font>]] page.

Revision as of 18:47, 20 October 2008

image page

iGEM 2008

image page



Project Details


Completed Systems



Engineering multi-functional probiotic bacteria

Engineered gut flora

The human gut houses a diverse collection of microorganisms, with important implications for the health and welfare of the host. We aim to engineer a member of this microbial community to provide innovative medical treatments. Our work focuses on four main areas: (1) pathogen defense, either by expression of pathogen-specific bacteriophage or by targeted bursts of reactive oxygen species; (2) prevention of birth defects by folate over-expression and delivery; (3) treatment of lactose intolerance, by cleaving lactose to allow absorption in the large intestine; and (4) regulation of these three treatment functions to produce renewable subpopulations specialized for each function. Our research demonstrates that synthetic biology techniques can be used to modify naturally occurring microbial communities for applications in biomedicine and biotechnology.

Why engineer gut microbes?

The large intestine: an ideal bioreactor

The human digestive tract

The human intestinal track is a perfect environment for bacteria. It is a 37°C mobile incubator with a constant stream of food. While bacteria are present in all parts of the intestinal track downstream of the stomach, the majority of those bacteria reside in the large intestine. There are approximately 1012 bacterial per mL in the large intestinal lumen, comprised of between 500-1000 different species of bacteria. Of these species, approximately 30 species compose 99% of all bacteria in the large intestine. Estimating there is roughly 100 mL of feces in the large intestine, all the bacteria in our gut outnumber all the cells in the human body 100 to 11.

Probiotic bacteria and other natural examples

Electron micrograph of Lactobacillus brevis, a probiotic lactic acid bacterium

Most of the bacteria in our gut have yet to be characterized because they are difficult to culture, owing to their sensitivity to oxygen. However, several species are known. Many bacterial laboratory strains are derived from the well-known Escherichia coli (a non-pathogenic type) which is normally present in the large intestine. Because of its use in research, E. coli is the most well characterized bacteria to date. Another bacteria, Bacteroides fragilis, plays an important role in proper development of the immune system and in controlling intestinal inflammation. Specifically, B. fragilis produces a starch called polysacharride A. In mice that had been raised in a sterile environment since birth (the intestinal track is initially sterile at birth and requires outside sources of bacteria to populate it), the immune system had less than normal levels of CD4+ killer T cells, a necessary white blood cell to battle infections. However the CD4+ levels returned to normal when the mice were raised again in a sterile environment, except for the presence of B. fragilis. Polysaccharide A alone, not the mere presence of Bacteroides fragilis, was responsible for the improvement, since mice raised with B. fragilis that could not produce polysaccharide A showed the same levels of CD4+ cell as the sterile mice2.

Several bacterial species can cause disease in humans by infecting the gut. E. coli is commonly associated with food poisoning. Salmonela enterica is responsible for typhoid fever. Campylobacter jejuni and Shigella can cause bowl inflammation, diarrhea and dysentery. Cholera is caused by Vibrio cholerae, which infected around 230,000 people and caused 6,300 deaths in 2006, according to the World Health Organization (WHO)[1]. These pathogens typically cause illness in otherwise healthy people. There are other, more opportunistic bacteria, which infect people in hospital setting who are otherwise sick or undergoing treatment that puts them at greater risk for infection of their intestinal track. Paradoxically, the treatment of one pathogen with antibiotics can make that same patient more susceptible to infection of their gut by opportunistic pathogens. It is thought that the right balance of natural gut flora prevent these opportunistic pathogens from colonizing the colon3.

As a further example, humans cannot produce Vitamin K, an important cofactor in blood clotting. Instead, the vitamin is provided by various species of the gut microbiota, which collectively produce more than 30 times the vitamin K recommended daily allowance4.

Nissle 1917: Probiotic, commercially available E. coli

Mutaflor - a commercially available preparation of Nissle 1917

Nissle 1917 is a commercially available[2] non-pathogenic, probiotic strain of E. coli. It has been successfully used to treat gastrointestinal disorders including colitis and intestinal bowel disease5 and shows little immunostimulatory activity6. Engineered versions of the Nissle 1917 strain have been developed as anti-HIV7 and anti-cholera8 agents. The ability of Nissle 1917 to efficiently colonize the gut without provoking an inflammatory response makes it an ideal chassis for in situ applications in biomedicine and biotechnology.

For more details, please see our project page.


  1. Hooper LV, Midtvedt T, and Gordon JI. How host-microbial interactions shape the nutrient environment of the mammalian intestine. Annu Rev Nutr 2002; 22 283-307.
  2. Mazmanian SK, Liu CH, Tzianabos AO, and Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005 Jul 15; 122(1) 107-18.
  3. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004 Jul 15; 39(2) 219-26.
  4. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr 1995; 15 399-417.
  5. Krammer HJ, Kamper H, von Bunau R, Zieseniss E, Stange C, Schlieger F, Clever I, and Schulze J. Probiotic drug therapy with E. coli strain Nissle 1917 (EcN): results of a prospective study of the records of 3,807 patients. Z Gastroenterol 2006 Aug; 44(8) 651-6.
  6. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, Schmidt MA, Buer J, and Bruder D. Intestinal immunity of Escherichia coli NISSLE 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 2005 Mar 1; 43(3) 373-84.
  7. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, and Hamer DH. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci U S A 2005 Aug 23; 102(34) 11993-8.
  8. Duan F and March JC. Interrupting Vibrio cholerae infection of human epithelial cells with engineered commensal bacterial signaling. Biotechnol Bioeng 2008 Sep 1; 101(1) 128-34.
Caltech logo.gif
Caltech footer.jpg